Epigenetic targeted anti-cancer drugs: An unfolding story

Oncology

Volumn 25, Issue 3, 2011, Pages

  Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

BIOLOGICAL ACTIVITY; DRUG MECHANISM; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE;

EID: 79953105427     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Wang H, Dymock BW. New patented histone deacetylase inhibitors. Expert Opinion Ther Pat. 2009;19:1727-57.
2. Wahhab A, Smil D, Ajamian A, et al. Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009;19:336-40.
3. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2009;102:3697-702. (Pubitemid 40354674)
4. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834-40.
5. Marks PA. Histone deacetylase inhibitors: a chemical approach to understanding cellular functions. Biochimica Biophysica Acta. 2010;1799:717-25.
6. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84-90. (Pubitemid 46087907)
7. Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010;107:14639-44.
8. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-8. (Pubitemid 46398669)
9. Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007;446:145-6. (Pubitemid 46398653)